AG
ADCT icon

Artal Group’s ADC Therapeutics ADCT Stock Holding History

Artal Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,018,461
Closed -$3.22M – 4
2024
Q2 		$3.22M Buy
+1,018,461
New +$4.05M 0.08% 67
2021
Q1 		– Sell
-95,000
Closed -$3.04M – 150
2020
Q4 		$3.04M Hold
95,000
– – 0.07% 117
2020
Q3 		$3.13M Sell
95,000
-41,000
-30% -$1.77M 0.08% 113
2020
Q2 		$6.37M Buy
+136,000
New +$5.16M 0.18% 95

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Artal Group's ADCT Position: Q3 2024 in Review

Artal Group sold out of ADC Therapeutics (ADCT) in Q3 2024, closing a stake of 1,018,461 shares — an estimated $3.22M sold.

Artal Group first reported a position in ADCT in Q2 2020 and held it in 4 quarters. The position peaked at $6.37M in Q2 2020. 77 funds tracked by Wall St. Rank hold ADCT as of Q3 2024.

  • Artal Group reported no remaining ADC Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 1,018,461 ADC Therapeutics shares in Q3 2024, an estimated $3.22M.
  • Artal Group first reported a position in ADC Therapeutics in Q2 2020 and held it in 4 quarters.
  • Artal Group's ADC Therapeutics position peaked at $6.37M in Q2 2020.
  • 77 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.